Background:Severe Acute Respiratory Syndrome (SARS-CoV-2), a zoonotic virus, is the pathogenic causal agent for the ongoing pandemic. Despite the lethality of the disease, there are no therapeutic agents available to combat the disease outbreak; and the vaccines currently accessible are insufficient to control the widespread, fast-mutating virus infection.Objective:This research study focuses on determining potential epitopes by examining the entire proteome of the SARS-CoV-2 virus using an in-silico approach.Methods:To design a vaccine for the deadly virus, the entire proteome of the SARS-CoV-2 virus was screened for identification of potential epitopes in order to identify the potent peptide candidate which is both unique and simultaneously solves the purpose of the vaccine discovery. It is mandatory to identify the suitable B-cell and T-cell epitopes of the observed SARS-CoV-2 Surface Glycoprotein (QKN61229.1). These epitopes were subjected to various tests, including antigenicity, allergenicity, and other physicochemical properties. The T-cell epitopes that met all of the criteria were then subjected to Population Coverage Analysis. It helped better understand the response of epitopes to the target population, compute the conservancy of a peptide, and then cluster them based on their sequence match, MHC binding, and T-cell restriction sites. Lastly, the interactions between the T-Cell Receptor (TCR) and a peptide-MHC were studied to gain a thorough understanding of MHC-restriction to design a peptide-vaccine.Results:The results showed that there were 4 B-Cell epitopes, 2 MHC-I epitopes, 4 MHC-II epitopes that qualified all the subjected tests and thus have an affinity to prominent antigens.Conclusion:ased on the results obtained from this study, the estimated peptides are a promising candidate for peptide-vaccine design and development.

中文翻译：

---

使用计算机内方法鉴定针对 SARS-CoV-2 的潜在免疫原性表位：免疫信息学研究

背景：严重急性呼吸系统综合症 (SARS-CoV-2) 是一种人畜共患病病毒，是当前大流行的致病因子。尽管这种疾病具有致命性，但没有可用于对抗疾病爆发的治疗剂；并且目前可获得的疫苗不足以控制广泛的、快速变异的病毒感染。目的：本研究的重点是通过使用计算机内方法检查 SARS-CoV-2 病毒的整个蛋白质组来确定潜在的表位。方法：为了设计致命病毒的疫苗，对 SARS-CoV-2 病毒的整个蛋白质组进行了筛选，以识别潜在的表位，以确定既独特又同时解决疫苗发现目的的强效候选肽。必须确定观察到的 SARS-CoV-2 表面糖蛋白 (QKN61229.1) 的合适 B 细胞和 T 细胞表位。这些表位经过各种测试，包括抗原性、过敏性和其他物理化学特性。然后对满足所有标准的 T 细胞表位进行群体覆盖分析。它有助于更​​好地了解表位对目标群体的反应，计算肽的保守性，然后根据它们的序列匹配、MHC 结合和 T 细胞限制性位点对它们进行聚类。最后，研究了T细胞受体（TCR）和肽-MHC之间的相互作用，以全面了解MHC的限制，从而设计肽-疫苗。结果：结果表明，有4个B细胞表位， 2个MHC-I表位，